IL2 and neoplasm: IL-2 promotes the expansion of regulatory T cells [51], therefore, the FLOT and CROSS chemotherapy-induced decrease in IL-2 production by T cells may in turn decrease regulatory T cell expansion and support development of anti-tumour immunity.